Is 1345.HK overvalued or undervalued?

1345.HK currently has a P/E ratio of 16.58. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Shanghai Pioneer Holding Ltd stock?

Shanghai Pioneer Holding Ltd trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 1345.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 1345.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 1345.HK to protect their purchasing power. Because 1345.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 1345.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 1345.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 1345.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks1345.HK

Shanghai Pioneer Holding Ltd

HK$2.08+HK$0.01+0.24%

HKSE / HKD

Market cap

HK$2.4B

P/E

16.6

EPS (TTM)

HK$0.02

Dividend yield

5.77%

Beta

-0.16

1Y return

+1.96%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$226M2021

$225M2022

$221M2023

$210M2024

$183M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.21Low
Current ratio2.51
Cash ratio0.36
Net margin9.9%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

1345.HK16.6
Healthcare sector median26.8
S&P 50022.0

Trades about 38% below its sector, cheaper than its peers on earnings.

Ratios

PEG0.70
Price to book1.98
EPS (TTM)HK$0.02
Payout ratio9,932%
FCF yield7.72%

Range & risk

HK$1.90HK$2.40

Trading in the middle of its 52-week band

Beta-0.16

Profile

What Shanghai Pioneer Holding Ltd actually does

China Pioneer Pharma Holdings Limited operates as an investment holding company, primarily focusing on the marketing, promotion, and distribution of pharmaceutical goods and medical devices within mainland China. The firm maintains an extensive portfolio of pharmaceutical products addressing diverse therapeutic areas, including ophthalmology, pain management, cardiovascular health, immunology, gynecology, and gastroenterology. Its medical device offerings encompass solutions for ophthalmology, orthopedics, dentistry, and wound care. The company supplies its products to a wide client base, including hospitals, various medical institutions, and pharmacies. Additionally, it engages in the sale of supporting tools, leases related equipment, provides dental apparatus, and distributes imported prescription products under license. Established in 1996, China Pioneer Pharma Holdings Limited is headquartered in Shanghai, PRC, and functions as a subsidiary of Pioneer Pharma (BVI) Co., Ltd.

CEO

Yuewen Yang

Employees

448

Headquarters

Shanghai, SH

Founded

2013-11-05

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 1345.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

1345.HK has a beta of -0.16, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Shanghai Pioneer Holding Ltd